Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

Koumarianou, Anna; Antoniou, Stavroula; Kanakis, George; Economopoulos, Nikolaos; Rontogianni, Dimitra; Ntavatzikos, Anastasios; Tsavaris, Nikolaos; Pectasides, Dimitrios; Dimitriadis, George; Kaltsas, Gregory

doi:10.1530/erc-11-0287

Cited by 55 publications

(54 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, bevacizumab has been studied in multiple small phase II clinical trials in combination with chemotherapies, including CAPOX, FOLFOX, and temozolomide (39)(40)(41)(42). Despite its demonstration of clinical activity in NETs in early phase clinical trials, the efficacy has not been confirmed in a requisite prospective, randomized phase III study.…”

Section: Bevacizumab and The Angiogenic Vegf Pathwaymentioning

confidence: 99%

Biologics in gastrointestinal and pancreatic neuroendocrine tumors

Liu

Kunz

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Section: Bevacizumab and The Angiogenic Vegf Pathwaymentioning

confidence: 99%

Biologics in gastrointestinal and pancreatic neuroendocrine tumors

Liu

Kunz

2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

“…A phase II study in combination with 2-methoxyestradiol revealed some degree of tumour reduction without achieving objective response according to RECIST response criteria (Kulke et al 2011). Bevacizumab has also been studied in phase II trials in NETs in combination with temozolomide, with higher response rates observed in pancreatic NET G2 (Chan et al 2012, Koumarianou et al 2012) and in combination with oxaliplatin and capecitabine, reaching an objective response rate of 23% (Kunz et al 2010). A randomised comparison of bevacizumab and octreotide vs IFN and octreotide is ongoing (NCT00569127).…”

Section: Inducing Angiogenesismentioning

confidence: 99%

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Walenkamp¹,

Crespo²,

Maya³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

In the past few years, there have been advances in the treatment of neuroendocrine tumours (NETs) and improvements in our understanding of NET biology. However, the benefits to patients have been relatively modest and much remains yet to be done. The 'Hallmarks of Cancer', as defined by Hanahan and Weinberg, provide a conceptual framework for understanding the aberrations that underlie tumourigenesis and to help identify potential targets for therapy. In this study, our objective is to review the major molecular characteristics of NETs, based on the recently modified 'Hallmarks of Cancer', and highlight areas that require further research.

show abstract

“…Partial responses were 57% with 9 months TTP. [24] It is noteworthy that 47% of patients had pNEN and 67% had an NEN with Ki67 less than or equal to 5%. The authors conclude that the very high RR suggested that prolonged administration of TMZ can induce a depletion of MGMT in favor of TMZ itself.…”

Section: Metronomic Chemotherapymentioning

confidence: 93%

“…Also a new way of chemotherapy administration is metronomic chemotherapy. [23,24] This overview details the evolution of SSAs and various chemotherapy combinations and their application to the management of NENs.…”

Section: Introductionmentioning

confidence: 99%

Review of recents advances in medical treatment for neuroendocrine neoplasms: somatostatin analogs and chemotherapy

Spada¹,

Valente²

2016

JCMT

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) are a heterogeneous group of rare tumours often producing high levels of hormones and causing symptoms. There are a number of different types of NENs. They usually arise as advanced and low/intermediate grade only in a minority of cases, as high grade. Treatment depends on which type and may include surgery, interventional radiology, and systemic treatment, including chemotherapy, somatostatin analogs, interferon α2b, peptide receptor radionuclide therapy, and only for pancreatic neuroendocrine tumors, molecular targeted agents, including everolimus and sunitinib. The aim of the article is to review the medical approaches with somatostatin analogs and chemotherapy. The treatment of NENs is mainly based on their biological characteristics of aggressiveness and functional features, such as symptoms and endocrine markers.

show abstract

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

Cited by 55 publications

References 12 publications

Biologics in gastrointestinal and pancreatic neuroendocrine tumors

Biologics in gastrointestinal and pancreatic neuroendocrine tumors

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Review of recents advances in medical treatment for neuroendocrine neoplasms: somatostatin analogs and chemotherapy

Contact Info

Product

Resources

About